Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability.

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque ...

Number 1: The competitive landscape for bone health treatments in the US has intensified with the FDA approval of Bildyos ...

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune thrombocytopenia, enhancing treatment accessibility. The romiplostim biosimilar ...